AMEX · RXL
Financial Services · Asset Management
$69.32
Down-$0.60 (-0.86%)
Updated Nov 4, 2026, 4:11 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RXL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
RXL closed at $69.32 after 21 trading sessions, up 20.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $69.00 | $70.415 | $69.00 | $69.3178 | 5.68K |
| Nov 2, 2026 | $69.76 | $70.3596 | $69.1601 | $70.0141 | 14.96K |
| Oct 30, 2026 | $71.45 | $71.45 | $70.055 | $70.16 | 35.85K |
| Oct 29, 2026 | $68.55 | $69.909 | $68.55 | $69.45 | 11.16K |
| Oct 28, 2026 | $65.44 | $67.02 | $65.44 | $66.3097 | 1.94K |
| Oct 27, 2026 | $65.21 | $66.05 | $65.21 | $65.95 | 4.51K |
| Oct 26, 2026 | $65.76 | $65.937 | $65.45 | $65.937 | 4.15K |
| Oct 23, 2026 | $66.97 | $66.97 | $65.685 | $65.97 | 7.35K |
| Oct 22, 2026 | $66.61 | $67.75 | $66.61 | $67.55 | 13.32K |
| Oct 21, 2026 | $64.92 | $66.11 | $64.88 | $65.8567 | 10.4K |
| Oct 20, 2026 | $64.76 | $66.51 | $64.76 | $66.44 | 14.81K |
| Oct 19, 2026 | $63.64 | $64.36 | $63.3401 | $63.51 | 17.18K |
| Oct 16, 2026 | $65.039 | $65.1099 | $64.05 | $64.22 | 11.25K |
| Oct 15, 2026 | $63.99 | $65.73 | $63.99 | $64.6412 | 10.16K |
| Oct 14, 2026 | $60.30 | $62.33 | $60.30 | $62.33 | 7.86K |
| Oct 13, 2026 | $61.50 | $61.50 | $59.3263 | $59.3263 | 29.22K |
| Oct 12, 2026 | $60.56 | $60.9856 | $60.51 | $60.934 | 2.12K |
| Oct 9, 2026 | $59.4143 | $60.30 | $59.4143 | $60.10 | 8.82K |
| Oct 8, 2026 | $57.57 | $58.3419 | $56.52 | $58.3419 | 5.12K |
| Oct 7, 2026 | $57.68 | $59.509 | $57.68 | $58.79 | 5.32K |
| Oct 6, 2026 | $57.91 | $57.91 | $56.98 | $57.72 | 2.51K |
The latest Smart Investors Daily articles mentioning RXL.
Company
Market Activity
Research & News
RXL research
Company profile and research snapshot.
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is designed to measure the stock performance of U.S. companies in the healthcare industry. Component companies include, among others, health care providers, biotechnology companies, medical supplies, advanced medical devices and pharmaceuticals. The fund is non-diversified.
Consensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 7, 2024
Rexel : Déclaration relative au nombre total d’actions et de droits de vote au titre de l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers
GlobeNewswire Inc. · Jun 7, 2024
Rexel: Statement relating to the total number of shares and voting rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Rules of the French Autorité des marchés financiers
GlobeNewswire Inc. · Jun 7, 2024
Powering Up Rexel to the next level Update on medium-term roadmap and upgraded financial targets presented at Capital Markets Day
GlobeNewswire Inc. · May 15, 2024
Paris, May 15, 2024
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RXL.
No results
No recent SID articles mention RXL.
